Association of <scp>FKBP5</scp> gene variants with depression susceptibility: A comprehensive meta‐analysis

Fan, Beifang; Ma, Jianping; Zhang, Huimin; Liao, Yuhua; Wang, Wanxin; Zhang, Sheng; Lu, Ciyong; Guo, Lan

doi:10.1111/appy.12464

Cited by 15 publications

(10 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…FKBP5 SNPs are highly correlated with depression development and responsiveness to antidepressant drug treatment. Previously, a meta-analysis of 16 independent studies including 5,125 patients with depression and 8,399 controls showed that the FKBP5 rs1360780 and rs4713916 polymorphisms were associated with depression, but there was no significant association for FKBP5 rs9470080 or rs9296158 ( 36 ). FKBP5 rs1360780 T + was significantly correlated with major depression, according to another meta-analysis finding ( 50 ).…”

Section: Discussionmentioning

confidence: 99%

“…After exposure to trauma, reducing GR sensitivity will impair HPA axis negative feedback, which will lead to an increase in cortisol levels. Cortisol is linked to a variety of stress-related mental disorders, including psychosis ( 31 ), borderline personality disorder ( 32 ), anxiety ( 33 , 34 ), schizophrenia ( 35 ), depression ( 36 , 37 ), PTSD, and suicidal tendencies ( 38 , 39 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The association of FKBP5 polymorphisms with the severity of depressive disorder in patients with methamphetamine use disorders

Fang¹,

Liu²,

Tian

et al. 2023

Front. Psychiatry

View full text Add to dashboard Cite

BackgroundCo-occurring depressive disorder (DD) in patients of methamphetamine use disorder (MAUD) impacts the diagnosis, treatment, and prognosis of the disease. Although FKBP5 has been associated with a variety of psychiatric disorders, whether FKBP5 influences depression susceptibility in MAUD is unknown so far.MethodsHere, we sequenced six FKBP5 single-nucleotide polymorphism (SNP) sites (rs4713916, rs6926133, rs9470080, rs737054, rs4713902, and rs9470079) in 282 methamphetamine users. MAUD and DD were evaluated by clinical questionnaires. SPSS was used to analyze the relationship between FKBP5 SNPs and DD in individuals with MAUD.ResultsOf the 282 methamphetamine users, 161 individuals met the MAUD criteria, and among them, 50 patients (31.1%) had DD co-occurring. Importantly, the incidence of DD in individuals with MAUD was 3.314 times greater than that of the methamphetamine users who did not meet the MAUD criteria (p < 0.001). Although none of the six SNPs of FKBP5 were correlated with the co-occurrence of DD in the population with MAUD, two FKBP5 alleles (rs4713916A and rs6926133A) were substantially associated with the higher DD scores in patients with MAUD (p < 0.05). Moreover, those with the two risk alleles do not have much higher scores than those with a single risk allele, and the strong linkage disequilibrium of the two SNPs may be the underlying cause of this result. Despite having weak linkage disequilibrium with either rs4713916 or rs6926133, FKBP5 rs9470079 became risky when paired with either.ConclusionThe results of this study revealed that the FKBP5 risk alleles (rs4713916A and rs6926133A) were associated with a greater probability of severe DD in patients with MAUD. These findings here would help with the development of biological early warning markers and the creation of personalized treatment strategies for MAUD.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The association of FKBP5 polymorphisms with the severity of depressive disorder in patients with methamphetamine use disorders

Fang¹,

Liu²,

Tian

et al. 2023

Front. Psychiatry

View full text Add to dashboard Cite

show abstract

“…All subjects were interviewed by trained interviewers using the Chinese version of the Semi-Structured Assessment for Drug Dependence and Alcoholism (SSADDA). The SSADDA was used to assess a variety of psychiatric disorders, including MAUD 23 , according to the Diagnostic and Statistical Manual of Mental Disorders, 4 th edition (DSM-4); the Chinese version of SSADDA has good reliability and validity in diagnosing MA dependence (according to DSM-4 criteria) and MAUD (according to DSM-5 criteria) 24,25 . We used the DSM-5 criteria in this study.…”

Section: Maud Diagnosis and Symptom Assessmentmentioning

confidence: 99%

Association of single nucleotide polymorphism and methylation of dopamine system-related genes with psychotic symptoms in patients of methamphetamine use disorders

Fang

Liu

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Methamphetamine use disorders (MAUD) can substantially jeopardize public security due to their high-risk social psychology and behavior. Given that the dopamine reward system is intimately associated with MAUD, we investigated the association of single nucleotide polymorphisms (SNPs), as well as methylation status of DRD4, COMT genes and paranoid, motor impulsive symptoms in MAUD patients. Methods: A total of 189 MAUD patients participated in our study. Samples of peripheral blood were used to detecte for 3 SNPs and levels of 35 CpG units of methylation in the DRD4 gene’s promoter region, 5 SNPs and 39 CpG units in the COMT gene. Results: MAUD patients with rs1800955 C allele have a lower percentage of paranoid symptom than those with rs1800955 TT. Individuals with paranoid symptom exhibited reduced methylation degree at particular DRD4 CpG2.3 unit. The interaction of the DRD4 rs1800955 C allele and the reduced DRD4 CpG2.3 methylation degree resulted in the lower occurrence of the paranoid symptom. Meanwhile, those with COMT rs4818 CC allele have lower motor impulsivity scores in MAUD patients, but greater COMT methylation levels in the promotor region and methylation degree at COMT CpG 51.52 unit. Therefore, based only on COMT rs4818 CC polymorphism, there was a negative correlation between COMT methylation and motor impulsivity scores in the MAUD patients. Conclusions: Our results found that the combination of SNP genotyping and methylation status of the DRD4 and COMT genes may serve as biological indicators to evaluate the prevalence of relatively high-risk psychotic symptoms in MAUD patients.

show abstract

“…Since the first report of a significant association of FKBP5 SNPs with depression in 2004, numerous studies have confirmed this association. Recently, a meta-analysis including 16 independent studies further supported FKBP5 polymorphisms as critical risk factors for depression . However, associations of FKBP51 are not exclusive for depression but have also been frequently reported for other stress-related psychiatric disorders, including post-traumatic stress disorder (PTSD), bipolar disorder, and schizophrenia .…”

Section: Introductionmentioning

confidence: 99%

“…Recently, a meta-analysis including 16 independent studies further supported FKBP5 polymorphisms as critical risk factors for depression. 14 However, associations of FKBP51 are not exclusive for depression but have also been frequently reported for other stress-related psychiatric disorders, including post-traumatic stress disorder (PTSD), 15 bipolar disorder, 16 and schizophrenia. 17 Interestingly, the increased risk of specific FKBP5 variants for psychiatric disorders is most apparent in interaction with stressful life events, such as childhood maltreatment and trauma.…”

mentioning

confidence: 99%

Analysis of the Selective Antagonist SAFit2 as a Chemical Probe for the FK506-Binding Protein 51

Buffa

Knaup

Heymann

et al. 2023

ACS Pharmacol. Transl. Sci.

View full text Add to dashboard Cite

The FK506-binding protein 51 (FKBP51) has emerged as an important regulator of the mammalian stress response and is involved in persistent pain states and metabolic pathways. The FK506 analog SAFit2 (short for selective antagonist of FKBP51 by induced fit) was the first potent and selective FKBP51 ligand with an acceptable pharmacokinetic profile. At present, SAFit2 represents the gold standard for FKBP51 pharmacology and has been extensively used in numerous biological studies. Here we review the current knowledge on SAFit2 as well as guidelines for its use.

show abstract

Association of FKBP5 gene variants with depression susceptibility: A comprehensive meta‐analysis

Cited by 15 publications

References 31 publications

The association of FKBP5 polymorphisms with the severity of depressive disorder in patients with methamphetamine use disorders

The association of FKBP5 polymorphisms with the severity of depressive disorder in patients with methamphetamine use disorders

Association of single nucleotide polymorphism and methylation of dopamine system-related genes with psychotic symptoms in patients of methamphetamine use disorders

Analysis of the Selective Antagonist SAFit2 as a Chemical Probe for the FK506-Binding Protein 51

Contact Info

Product

Resources

About